Guideline of the Spanish Society of Nephrology on kidney and cardiovascular diseases. Shortened version;Guía de la Sociedad Española de Nefrología sobre riñón y enfermedad cardiovascular. Versión abreviada

Nefrologia

Volumn 26, Issue 1, 2006, Pages 31-44

  Marín, Rafaël ^a   Goicoechea, M A ^b   Gorostidi, M ^c   Cases, A ^d   Diez J ^e   Escolar, G ^d   Fernandez Vega F ^a   Palomar, R ^f   Rodrigo, E ^f   Martinez I ^g   Segura, J ^h  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL SAN AGUSTÍN   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL DE GALDAKAO   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CASE MANAGEMENT; CHRONIC DISEASE; CLINICAL TRIAL; COMORBIDITY; DISEASE PREDISPOSITION; DRUG EFFECT; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MEDICAL SOCIETY; NEPHROLOGY; PRACTICE GUIDELINE; PREVALENCE; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SPAIN;

ALGORITHMS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CASE MANAGEMENT; CHRONIC DISEASE; CLINICAL TRIALS; COMORBIDITY; DISEASE SUSCEPTIBILITY; HEALTH SURVEYS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; NEPHROLOGY; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SOCIETIES, MEDICAL; SPAIN;

EID: 33746821565     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW y cols.: National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003.
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL y cols.: Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003.
3. Marín R, Goicoechea MA, Gorostidi M, eds: Guías SEN. Riñón y enfermedad cardiovascular. Nefrología 24 (Supl. 6): S1-S235, 2004.
4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39 (Supl. 1): S1-S266, 2002.
5. Levey AS, Bosch JP, Breyer-Lewis J, Greene T, Rogers N, Roth A: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130: 461-470, 1999.
6. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.
7. Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, y cols.: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100, 2005.
8. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB y cols.: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352: 2049-2060, 2005.
9. Iseki K, Ikemiya Y, Iseki C, Takishita S: Proteinuria and the risk of developing end-stage renal disease. Kidney Int 63: 1468-1474, 2003.
10. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL y cols.: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315, 2004.
11. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL y cols.: Kidney disease as a risk factor to recurrent cardiovascular disease and mortality. Am J Kidney Dis 44: 198-206, 2004.
12. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalisation. N Engl J Med 351: 1296-1305, 2004.
13. Gerstein HC, Mann JF, Yi Q, ZinmFidleran B, Dinneen SF, Hoogwerf B y cols for the HOPE study investigators: albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426, 2001.
14. Hillege HL, Fidler V, Diercks GF, Van Gilst WH, De Zeeuw D, Van Veldhuisen DJ for the Prevention of Renal and Vascular End Stage Disease (PREVENU) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782, 2002.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL y cols.: Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42: 1206-52, 2003.
16. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C y cols.: Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293: 1737-1745, 2005.
17. Hailpern SM, Cohen HW, Alderman MH: Renal dysfunction and ischemic heart disease mortality in a hypertensive population. J Hypertens 23: 1809-1816, 2005.
18. O'Hare AM, Bertenthal D, Shlipak MC, Sen S, Chren MM: Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol 16: 514-519, 2005.
19. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 4: 1-12, 2003.
20. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA y cols.: Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol 16: 180-188, 2005.
21. de Zeeuw D, Hillege HL, De Jong PE: The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int 68 (Supl. 98): S25-S29, 2005.
22. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ y cols.: Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 14: S131-S138, 2003.
23. Otero A, Abelleira A, Gayoso P: Enfermedad renal crónica oculta y factures de riesgo vascular asociados. Estudio epidemiológico. Nefrología 25: 275-286, 2005.
24. Dirks JH, de Zeeuw D, Agarwal SK, Atkins RC, Correa-Rotter R, D'Amico G y cols.: Prevention of chronic kidney and vascular disease: toward global health equity. The Bellagio 2004 Declaration. Kidney Int: 68 (Supl. 98): S1-S6, 2005.
25. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J y cols.: Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 38: 1398-1407, 2001.
26. Gorostidi M, Marín R: Nefropatía vascular. Concepto y significado. Epidemiología. Hipertension arterial esencial e insuficiencia renal. Nefroesclerosis. Nefrología 24 (Supl. 6): S73-S83, 2004.
27. Górriz JL, Sancho A, Pallardó LM, Amoedo ML, Barril G, Salgueira M y cols.: Longer pre-dialysis nephrological care is associated with improved long-term survival of dialysis patients. More facts. Nephrol Dial Transplant 17: 1354-1355, 2002.
28. Kazmi WH, Obrador GT, Khan SS, Pereira BJG, Kausz AT: Late Nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. Nephrol Dial Transplant 19: 1808-1814, 2004.
29. Hosteller TH: Chronic kidney disease predicts cardiovascular disease. N Engl J Med 351: 1344-1347, 2004.
30. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL y cols.: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004.
31. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45 (Supl. 3): S1-S153, 2005.
32. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ y cols.: The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease study. Ann Intern Med 142: 342-351, 2005.
33. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R y cols for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group: preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 36: 646-661, 2000.
34. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, De Jong PE, De Zeeuw D y cols for the AIPRD Study Group: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Intern Med 139: 244-252, 2003.
35. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (Supl. 1): S1-S290, 2004.
36. Brenner BM: Retarding the progression of renal disease. Kidney Int 64: 370-378, 2003.
37. Zandi-Nejad K, Brenner BM: Primary and secondary prevention of chronic kidney disease. J Hypertens 23: 1771-1778, 2005.
38. Gorostidi M, Marín R: Tratamiento de la hipertensión arterial en enfermos con insuficiencia renal. Estadios 2 y 3 de la enfermedad renal crónica. Nefrología 24 (Supl. 6): 91-100, 2004.
39. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA: Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 14: 3217-3232, 2003.
40. Segura J: Bloqueo del sistema renina-angiotensina. Nefrología 24 (Supl. 6): 101-112, 2004.
41. 40a. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366: 2026-33, 2005.
42. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993.
43. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997.
44. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB y cols for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
45. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH y cols for the RENAAL Study Investigators: effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
46. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 361: 117-124, 2003.
47. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch Intern Med 160: 685-693, 2000.
48. Hörl MP, Hörl WH: Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 29: 227-244, 2002.
49. Fishbane SA, Scribner BH: Blood pressure control in dialysis patients. Semin Dial 15: 144-145, 2002.
50. Locatelli F, Covic A, Chazot C, Leunissen K, Luno J, Yaqoob M: Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant 19: 1058-1068, 2004.
51. Luik AJ, Van der Sande FM, Weideman P, Cheriex E, Kooman JP, Leunissen KM: The influence of increasing dialysis treatment time and reducing dry weight on blood pressure control in haemodialysis patients: a prospective study. Am J Nephrol 21: 471-478, 2001.
52. Griffith TB, Chua BSY, Allen AS, Klassen PS, Donal NR, Szczech LA: Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 42: 1260-1269, 2003.
53. Kiss I, Farsang C, Rodicio JL: Treatment of hypertension in dialysed patients. J Hypertens 23: 222-226, 2005.
54. Santos SFF, Peixoto AJ: Hypertension in dialysis. Curr Opin Nephrol Hypertens 14: 111-118, 2005.
55. Mange KC, Cizman B, Joffe M, Feldman HI: Arterial hypertension and renal allograft survival. JAMA 283: 633-638, 2000.
56. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11: 1910-1917, 2000.
57. National Kidney Foundation K/DOQI clinical practice guidelines on managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 41 (Supl. 3): S1-S77, 2003.
58. Farbakhsh K, Kasiske BL: Dyslipidemias in patients who have chronic kidney disease. Med Clin North Am 89: 689-699, 2005.
59. Brotons C, Royo Bordonoba MA, Álvarez-Sala L, Armario P, Artigao R y cols.: Adaptación española de la Guía Europea de Prevención Cardiovascular. Nefrología 24: 312-328, 2004.
60. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G y cols.: German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005.
61. Antithrombotic Trialists' Collaboration: Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324: 71-86, 2002.
62. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B y cols.: Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 25: 166-181, 2004.
63. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A y cols.: First United Kingdom Heart and Renal Protection (UK-HARP-1) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45: 473-484, 2005.
64. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA y cols.: Prevention of venous thromboembolism. Chest 119: 132S-175S, 2001.
65. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL y cols.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 38: 1231-1266, 2001.
66. Lo DS, Rabbat CG, Clase CM: Thromboembolism and anticoagulant management in hemodialysis patients: a practical guide to clinical management. Thromb Res 2005 (en prensa).
67. Rostand SG: Coronary heart disease in chronic renal insufficiency: some management considerations. J Am Soc Nephrol 11: 1948-1956, 2000.
68. Sarnak MK: Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 41 (Supl. 5): S11-S17, 2003.
69. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL y cols.: Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to know? Where do we go from here? Special report from the National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906, 1998.
70. Stevinkel P, Pecoits-Filho R, Lindholm B: Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003 14: 1927-1939, 2003.
71. Hujairi NMA, Afzali B, Goldsmith DJA: Cardiac calcification in renal patients: what we do and don't know. Am J Kidney Dis 43: 234-243, 2004.
72. Umana E, Ahmed W, Alpert MA: Valvular and perivalvular abnormalities in end-stage renal disease. Am J Med Sci 325: 237-242, 2003.
73. O'Hare A, Johansen K: Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol 12: 2838-2847, 2001.
74. Furie K: Stroke prevention. N Engl J Med 346: 213-214, 2001.
75. Maeda N, Sawayama Y, Tatsukawa M, Okada K, Furusyo N, Shigematsu M y cols.: Carotid artery lesions and atherosclerotic risk factors in Japanese haemodialysis patients. Atherosclerosis 169: 183-192, 2003.
76. Miller LW: Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2: 807-818, 2002.
77. Campistol JM: Riesgo cardiovascular en el paciente trasplantado renal. Nefrología 22 (Supl. 4): 7-11, 2002.
78. Ritz E, Schwenger V, Wiesel M, Zeier M: Atherosclerotic complications after renal transplantation. Transpl Int 13 (Supl. 1): S14-S19, 2000.
79. Matas AJ, Humar A, Gilligham KJ, Payne WD, Gruessner RW, Kandaswamy R y cols.: Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 62: 704-714, 2002.
80. Goldsmith DJA, Covic A: Coronary artery disease in uremia: etiology, diagnosis and therapy. Kidney Int 60: 2059-2078, 2001.
81. Gill JS, Ma I, Landsberg D, Johnson N, Levin A: Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation. J Am Soc Nephrol 16: 808-816, 2005.
82. Logar CM, Herzog CA, Beddhu S: Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations. Am J Med Sci 325: 214-227, 2003.